FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116250344> ?p ?o ?g. }

• W2116250344 endingPage "454" @default.
• W2116250344 startingPage "449" @default.
• W2116250344 abstract "Background Local complications (encapsulation, rashes, rupture, and leakage) can occur after placement of silicone-gel-containing breast implants (SBI). Whether SBI exposure results in systemic manifestations in some recipients is controversial. We have carried out a blinded study to assess whether there is any difference between SBI recipients and non-exposed controls in the proportions positive for serum antibodies directed against polymeric substances. Methods We recruited female SBI recipients (including those without symptoms) who presented to a single rheumatology clinic. A physician global assessment was used to classify SBI recipients who did not meet criteria for specific autoimmune diseases according to the severity of local and systemic signs and symptoms. Controls were recruited from among clinic staff and their acquaintances. Results of the antipolymer antibody (APA) assay were compared with those of an assay for antinuclear antibodies (ANA) and with the severity of the signs and symptoms. Findings Positive APA results were found in one (3%) of 34 SBI recipients with limited symptoms, two (8%) of 26 with mild symptoms, seven (44%) of 16 with moderate symptoms, and 13 (68%) of 19 with advanced symptoms. Four (17%) of 23 healthy non-SBI-exposed controls and two (10%) of 20 non-exposed women with classic autoimmune diseases were positive for APA Thus, women with moderate or advanced symptoms were significantly more likely than those with limited or mild symptoms, or non-exposed controls to have APA (p<0·001). The proportion with positive ANA results was higher for women with classic autoimmune diseases 14 (70%) of 20 than for any SBI-exposed subgroup (0·33%). Interpretation The APA assay can objectively contribute to distinguishing between SBI recipients with limited or mild signs and symptoms, SBI recipients with more severe manifestations, and patients with specific autoimmune diseases. Further studies will be needed to define the signs and symptoms associated with exposure to SBI." @default.
• W2116250344 created "2016-06-24" @default.
• W2116250344 creator A5016090653 @default.
• W2116250344 creator A5024649406 @default.
• W2116250344 creator A5024924406 @default.
• W2116250344 creator A5030920638 @default.
• W2116250344 creator A5034805824 @default.
• W2116250344 creator A5035079203 @default.
• W2116250344 creator A5035816229 @default.
• W2116250344 creator A5048967469 @default.
• W2116250344 creator A5049927956 @default.
• W2116250344 creator A5057467364 @default.
• W2116250344 creator A5065123363 @default.
• W2116250344 creator A5073021926 @default.
• W2116250344 creator A5073316716 @default.
• W2116250344 creator A5078822210 @default.
• W2116250344 date "1997-02-01" @default.
• W2116250344 modified "2023-10-18" @default.
• W2116250344 title "Use of antipolymer antibody assay in recipients of silicone breast implants" @default.
• W2116250344 cites W1979123530 @default.
• W2116250344 cites W1985699107 @default.
• W2116250344 cites W2002400916 @default.
• W2116250344 cites W2004367604 @default.
• W2116250344 cites W2021625060 @default.
• W2116250344 cites W2036464038 @default.
• W2116250344 cites W2041584266 @default.
• W2116250344 cites W2047142333 @default.
• W2116250344 cites W2076646798 @default.
• W2116250344 cites W2087273022 @default.
• W2116250344 cites W2088158803 @default.
• W2116250344 cites W2088767128 @default.
• W2116250344 cites W2090361738 @default.
• W2116250344 cites W2092190965 @default.
• W2116250344 cites W2126673691 @default.
• W2116250344 cites W2337028688 @default.
• W2116250344 cites W2339651551 @default.
• W2116250344 cites W4243382159 @default.
• W2116250344 cites W4243497154 @default.
• W2116250344 cites W4300466227 @default.
• W2116250344 doi "https://doi.org/10.1016/s0140-6736(96)07131-0" @default.
• W2116250344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9040573" @default.
• W2116250344 hasPublicationYear "1997" @default.
• W2116250344 type Work @default.
• W2116250344 sameAs 2116250344 @default.
• W2116250344 citedByCount "51" @default.
• W2116250344 countsByYear W21162503442013 @default.
• W2116250344 countsByYear W21162503442017 @default.
• W2116250344 countsByYear W21162503442021 @default.
• W2116250344 crossrefType "journal-article" @default.
• W2116250344 hasAuthorship W2116250344A5016090653 @default.
• W2116250344 hasAuthorship W2116250344A5024649406 @default.
• W2116250344 hasAuthorship W2116250344A5024924406 @default.
• W2116250344 hasAuthorship W2116250344A5030920638 @default.
• W2116250344 hasAuthorship W2116250344A5034805824 @default.
• W2116250344 hasAuthorship W2116250344A5035079203 @default.
• W2116250344 hasAuthorship W2116250344A5035816229 @default.
• W2116250344 hasAuthorship W2116250344A5048967469 @default.
• W2116250344 hasAuthorship W2116250344A5049927956 @default.
• W2116250344 hasAuthorship W2116250344A5057467364 @default.
• W2116250344 hasAuthorship W2116250344A5065123363 @default.
• W2116250344 hasAuthorship W2116250344A5073021926 @default.
• W2116250344 hasAuthorship W2116250344A5073316716 @default.
• W2116250344 hasAuthorship W2116250344A5078822210 @default.
• W2116250344 hasConcept C126322002 @default.
• W2116250344 hasConcept C149443304 @default.
• W2116250344 hasConcept C159654299 @default.
• W2116250344 hasConcept C163764329 @default.
• W2116250344 hasConcept C178790620 @default.
• W2116250344 hasConcept C185592680 @default.
• W2116250344 hasConcept C198451711 @default.
• W2116250344 hasConcept C203014093 @default.
• W2116250344 hasConcept C2779769944 @default.
• W2116250344 hasConcept C71924100 @default.
• W2116250344 hasConcept C90924648 @default.
• W2116250344 hasConceptScore W2116250344C126322002 @default.
• W2116250344 hasConceptScore W2116250344C149443304 @default.
• W2116250344 hasConceptScore W2116250344C159654299 @default.
• W2116250344 hasConceptScore W2116250344C163764329 @default.
• W2116250344 hasConceptScore W2116250344C178790620 @default.
• W2116250344 hasConceptScore W2116250344C185592680 @default.
• W2116250344 hasConceptScore W2116250344C198451711 @default.
• W2116250344 hasConceptScore W2116250344C203014093 @default.
• W2116250344 hasConceptScore W2116250344C2779769944 @default.
• W2116250344 hasConceptScore W2116250344C71924100 @default.
• W2116250344 hasConceptScore W2116250344C90924648 @default.
• W2116250344 hasIssue "9050" @default.
• W2116250344 hasLocation W21162503441 @default.
• W2116250344 hasLocation W21162503442 @default.
• W2116250344 hasOpenAccess W2116250344 @default.
• W2116250344 hasPrimaryLocation W21162503441 @default.
• W2116250344 hasRelatedWork W1970898494 @default.
• W2116250344 hasRelatedWork W2049031445 @default.
• W2116250344 hasRelatedWork W2332116053 @default.
• W2116250344 hasRelatedWork W2369071334 @default.
• W2116250344 hasRelatedWork W2369767863 @default.
• W2116250344 hasRelatedWork W2401624759 @default.
• W2116250344 hasRelatedWork W3158350442 @default.
• W2116250344 hasRelatedWork W4223489734 @default.

• next